Blanca Ledezma
Hematology & Oncology · Santa Monica, CANPI 1124253323
Payments from drug & device makers
Across 585 payments — averaging $328.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$68K
- AstraZeneca$57K
- Amgen$19K
- Daiichi Sankyo Inc.$13K
- Eisai Inc.$10K
- Pfizer$9K
- plus $16K from 28 others
What the payments were for
- Consulting fees$25,16313%
- Speaking & faculty fees$129,79068%
- Travel & lodging$26,10714%
- Food & beverage$10,3465%
- Education$5880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 163 | $67,844 |
| AstraZeneca | 124 | $57,261 |
| Amgen | 49 | $18,796 |
| Daiichi Sankyo Inc. | 40 | $12,644 |
| Eisai Inc. | 45 | $9,880 |
| Pfizer | 29 | $9,297 |
| Johnson & Johnson(2 entities) | 6 | $4,377 |
| Astrazeneca UK Limited | 4 | $3,650 |
| Helsinn Therapeutics (U.S.), Inc. | 6 | $1,914 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,480 |
| Janssen Scientific Affairs, LLC | 2 | $1,055 |
| E.r. Squibb & Sons, L.L.C. | 2 | $858 |
| Bayer | 25 | $484 |
| AbbVie | 12 | $315 |
| Genentech USA, Inc. | 11 | $272 |
| Stemline Therapeutics Inc. | 4 | $199 |
| Novartis | 7 | $177 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $174 |
| GSK | 3 | $173 |
| Puma Biotechnology, Inc. | 7 | $172 |
| Incyte Corporation | 4 | $148 |
| Bristol Myers Squibb | 6 | $136 |
| Tempus AI, Inc | 2 | $112 |
| Gilead | 4 | $87 |
| Merck | 3 | $84 |
| Array Biopharma Inc | 3 | $83 |
| Seagen Inc. | 3 | $70 |
| Sanofi | 2 | $54 |
| Novocure Inc. | 1 | $53 |
| Beigene USA, Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$191,994 in reported general payments places this provider in the 75th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 26 | $408,517 |
| LumakrasSotorasib | 11 | $246,873 |
| EliquisApixaban | 36 | $23,462 |
| Abiraterone Acetate | 11 | $1,423 |
| Dexamethasone | 32 | $841 |
| Hydroxyurea | 18 | $510 |
| Ondansetron OdtOndansetron | 32 | $428 |
| Nystatin | 15 | $359 |
| Prochlorperazine Maleate | 33 | $328 |
| Ondansetron Hcl | 20 | $183 |
| Oxycodone Hcl | 21 | $168 |
| Hydrocortisone | 18 | $123 |
| Methylprednisolone | 11 | $117 |
| Tramadol Hcl | 17 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $57,261 | $408,51726 claims |
| AmgenLumakras | $18,796 | $246,87311 claims |
| PfizerEliquis | $9,297 | $23,46236 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,055 | $1,42311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Monica
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Aditya BardiaSanta Monica$22.1M
- Zev WainbergSanta Monica$19.3M
- Richard FinnSanta Monica$9.9M
- Aaron LisbergSanta Monica$9.6M
- Steven OdaySanta Monica$3.7M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.